Press Releases

EMERYVILLE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that Aprinnova, its joint venture with NIKKOL GROUP ("NIKKOL"), has launched pharmaceutical grade Neossance® Squalane USP. This new material meets the industry standards required by the United States Pharmacopeia (USP) and the National Formulary (NF) for drug actives and pharmaceutical excipients, which are used by regulatory agencies and manufacturers to ensure products have the appropriate identity, quality, purity, and consistency. As a result, Aprinnova is now able to supply these industries with FDA-regulated sugarcane-derived squalane, which was previously unavailable to these markets since shark-derived squalane was the only source reference in the regulatory monograph for squalane.

Amyris's Aprinnova cosmetic ingredients joint venture has now delivered over 50% annual revenue growth since the joint venture was announced and is the leading source of one of the world's leading natural skin nourishment ingredients. This approval enables significant expansion of this business across numerous product applications. These include topical and dermal cosmetic applications such as therapeutic skin creams and ointments.

"We are very pleased to have met the USP and NF requirements, which showcases our adherence to a philosophy of manufacturing and distributing the highest performance, sustainable products through a best-in-class production process," said Caroline Hadfield, Senior Vice President of Personal Care at Amyris. "We are delighted to provide a sustainable and naturally-sourced squalane to this important new market for Aprinnova while providing our customers and their end market customers with non-animal, cruelty-free high-performance ingredients for a growing variety of products."

About Amyris

Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the expected expansion of the Aprinnova business across numerous product applications, including topical and dermal cosmetic applications such as therapeutic skin creams and ointments), that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo, Aprinnova, the Aprinnova logo, No Compromise, and Neossance are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries. All other trademarks are the property of their respective owners.

Contact:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc. 
+1 (510) 740-7481
investor@amyris.com
pr@amyris.com